Back to News
Market Impact: 0.25
AbbVie Collaborates With Iambic On AI-Powered Discovery And Development Of Small Molecule Therapies
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
AbbVie announced a multi-year collaboration with clinical-stage life sciences technology company Iambic to accelerate discovery and development of small-molecule therapies in immunology. The partnership targets first-in-class and best-in-class candidates, providing a positive signal for AbbVie's early-stage pipeline, though no financial terms or development milestones were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ABBV0.55
More News
- HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Asian Markets Tally Losses From Worsening Global Rout
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears